免疫治疗联合化疗在中晚期非小细胞肺癌治疗中的应用效果研究

The clinical efficacy of immunotherapy combined with chemotherapy in the treatment of non-small cell lung cancer

目的探讨免疫治疗联合化疗在中晚期非小细胞肺癌(NSCLC)治疗中的疗效。方法将186例中晚期NSCLC患者作为研究对象,按照分层随机分组法将患者分为两组,对照组88例给予单纯化疗,观察组98例给予免疫治疗联合化疗,观察两组患者临床症状积分、临床疗效、免疫功能及不良反应发生率。随访2年,比较两组患者远期生存情况。结果治疗后观察组临床症状积分明显低于对照组,而临床有效率及受益率高于对照组,差异均有统计学意义(P﹤0.01)。治疗后观察组外周血T淋巴细胞亚群比例明显高于对照组,差异有统计学意义(P﹤0.01)。两组患者不良反应发生率比较,差异无统计学意义(P﹥0.05)。随访2年,观察组患者2年生存率及中位生存时间高于对照组,差异有统计学意义(P﹤0.05)。结论免疫治疗联合化疗能有效缓解患者临床症状,提高临床化疗效果及免疫功能,在中晚期非小细胞肺癌治疗中具有较高应用价值。

Objective To explore the clinical efficacy of immunotherapy combined with chemotherapy in the treat-ment of advanced non-small cell lung cancer （NSCLC）. Method 186 patients with advanced NSCLC were enrolled in the study, and were randomized as study group, receiving immunotherapy＋chemotherapy （n=98）, and control group, ad-ministered with chemotherapy alone （n=88）;the score of clinical symptom, clinical efficacy, immune function and the ad-verse reactions in the two groups were observed. The long-term survival of both groups were compared during 2-year fol-low-up. Result The study group had a significantly lower score of clinical symptom, and higher clinical response rate and benefit rate compared with those of the control group （P〈0.05）. The proportion of T lymphocyte subsets in peripheral blood was higher in study group than that in control group after treatment, with significant difference observed （P〈0.01）. The incidences of adverse reactions were comparable between the two groups （P〉0.05）. The 2-year survival rate and me-dian survival time were all significantly higher in study group compared with that in control group in the 2-year follow up （P〈0.05）. Conclusion Immunotherapy combined with chemotherapy is fairly effective in improving clinical symptoms, increasing efficacy of chemotherapy and immune function, which is of important clinical value in the treatment of non-small cell lung cancer.